EVLOEvelo Biosciences, Inc.

About Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. (EVLO) is a Biotechnology company headquartered in Foxborough, MA, United States whose shares trade over-the-counter on the Expert Market tier.

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.

EVLO key facts

Ticker symbol

EVLO

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Foxborough, MA, United States

Country of incorporation

US

Estimated market cap

$9.5K (as of Apr 16, 2025)

Shares outstanding

18,930,960

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with E